antiproliferative activity
drug resistance
organometallic complexes
platinum
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
19 Jan 2022
19 Jan 2022
Historique:
received:
14
12
2021
revised:
14
01
2022
accepted:
15
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
1
4
2022
Statut:
epublish
Résumé
The high incidence of the resistance phenomenon represents one of the most important limitations to the clinical usefulness of cisplatin as an anticancer drug. Notwithstanding the considerable efforts to solve this problem, the circumvention of cisplatin resistance remains a challenge in the treatment of cancer. In this work, the synthesis and characterization of two
Identifiants
pubmed: 35163916
pii: molecules27030644
doi: 10.3390/molecules27030644
pmc: PMC8838190
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Organoplatinum Compounds
0
Platinum
49DFR088MY
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Dipartimento di Scienze del Farmaco-Università di Padova
ID : PRID 2017 (DALL_SID17_02)
Organisme : Pisa University
ID : 2020-PRA_2020_39
Références
Front Pharmacol. 2015 Apr 24;6:85
pubmed: 25964760
J Inorg Biochem. 2021 Mar;216:111335
pubmed: 33360320
Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
pubmed: 17380161
Dalton Trans. 2012 Jan 28;41(4):1389-96
pubmed: 22124431
Nat Rev Cancer. 2009 May;9(5):327-37
pubmed: 19377505
Food Chem Toxicol. 2020 Feb;136:111079
pubmed: 31891754
Eur J Pharm Biopharm. 2021 Jun;163:60-71
pubmed: 33775853
Adv Cancer Res. 2021;152:305-327
pubmed: 34353441
Br J Cancer. 2008 Jun 17;98(12):1910-5
pubmed: 18506140
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Bioorg Med Chem. 2013 Nov 15;21(22):6965-72
pubmed: 24095013
Oncol Lett. 2020 Nov;20(5):232
pubmed: 32968454
Nat Rev Drug Discov. 2004 Jan;3(1):11-2
pubmed: 14756144
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
J Cancer. 2020 Apr 25;11(14):4181-4192
pubmed: 32368301
Biochem Biophys Res Commun. 1993 Nov 30;197(1):40-5
pubmed: 8250945
Oncotarget. 2018 Jun 1;9(42):26701-26710
pubmed: 29928479
In Vivo. 2020 Nov-Dec;34(6):3483-3487
pubmed: 33144457
Cell Death Dis. 2014 May 29;5:e1257
pubmed: 24874729
Semin Oncol Nurs. 1989 May;5(2 Suppl 1):63-9
pubmed: 2657932
J Nephrol. 2018 Feb;31(1):15-25
pubmed: 28382507
J Biol Inorg Chem. 2011 Jun;16(5):695-713
pubmed: 21594772
Bioorg Med Chem. 2016 Jul 1;24(13):2929-2937
pubmed: 27179449
Nat Rev Cancer. 2009 May;9(5):338-50
pubmed: 19377506
J Med Chem. 2007 May 3;50(9):2194-9
pubmed: 17407274
Best Pract Res Clin Endocrinol Metab. 2012 Dec;26(6):711-23
pubmed: 23168274
Tumour Biol. 2014 Jan;35(1):179-87
pubmed: 23897556
Semin Cancer Biol. 2021 Dec;77:167-181
pubmed: 32871277
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
Dalton Trans. 2008 Dec 7;(45):6393-400
pubmed: 19002325
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
ChemMedChem. 2021 Jun 17;16(12):1956-1966
pubmed: 33751814
ChemMedChem. 2020 Aug 5;15(15):1464-1472
pubmed: 32490604
Int J Mol Sci. 2020 Dec 04;21(23):
pubmed: 33291532
Dalton Trans. 2012 Feb 21;41(7):2066-77
pubmed: 22183160
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
J Photochem Photobiol B. 2014 Sep 5;138:63-74
pubmed: 24911273